In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
no speaker photo
Speaker
Peter Van Der Meer
Peter Van Der Meer Peter Van Der Meer

University Medical Center Groningen, Groningen (Netherlands (The))

Specialities : Acute Heart Failure , Basic Science

28 presentations from this speaker

Cardiac amyloidosis: an emerging target in HFpEF?

Event : Heart Failure 2019

  • Session : Reshaping the future of heart failure management - Translating innovations to practice in HFpEF
  • Speaker : P Van Der Meer (Groningen,NL)
  • Organised by PACE-CME - Physicians' Academy for Cardiovascular Education, supported with educational grants provided by Novartis, Novo Nordisk and Pfizer

Cardio-Oncology - Where have we come from in the last 20 years?

Event : Heart Failure 2019

  • Session : Cardio-Oncology in 2019 - The new frontier
  • Speaker : P Van Der Meer (Groningen,NL)
  • Joint Session with ESC Council of Cardio-Oncology

Iron deficiency in heart failure: what do we know in 2019?

Event : Heart Failure 2019

  • Session : Management of iron deficiency in heart failure: implementing best practices to improve patient outcomes
  • Speaker : P Van Der Meer (Groningen,NL)
  • Organised by MedEd Global Solutions & Charité Universitätsmedizin Berlin, supported with an educational grant from Vifor Pharma

A patient with HFpEF and renal dysfunction - What do the guidelines say?

Event : Heart Failure 2018

  • Session : Guidelines in daily practice V - HFpEF
  • Speaker : P Van Der Meer (Groningen,NL)

A patient with hypotension and pulmonary oedema - What do the guidelines say?

Event : Heart Failure 2018

  • Session : Guidelines in daily practice II - Acute heart failure
  • Speaker : P Van Der Meer (Groningen,NL)

Conclusions - Diagnostics and continuous monitoring for prevention of heart failure deterioration: a new multi-sensor approach and considerations for the patient care pathway.

Event : Heart Failure 2018

  • Session : Diagnostics and continuous monitoring for prevention of heart failure deterioration: a new multi-sensor approach and considerations for the patient care pathway
  • Speaker : P Van Der Meer (Groningen,NL)
  • Sponsored by Boston Scientific

Heart failure – How to treat in 2018.

Event : ESC Congress 2018

  • Session : Key messages from the most popular ESC webinars
  • Speaker : J Cleland (Glasgow,GB), P Van Der Meer (Groningen,NL)
  • ESC Education committee

Iron deficiency management – impact on clinically important outcomes.

Event : ESC Congress 2018

  • Session : Co-morbidities in chronic heart failure – time for paradigm shifts in the management of hyperkalaemia and iron deficiency
  • Speaker : P Van Der Meer (Groningen,NL)
  • Organised by Charité supported with an educational grant from Vifor

Iron deficiency: an important comorbidity - Discussion and questions.

Event : Heart Failure 2018

  • Session : Iron deficiency: an important comorbidity
  • Speaker : S Anker (Berlin,DE), P Van Der Meer (Groningen,NL), CS Lam (Singapore,SG), EA Jankowska (Wroclaw,PL)
  • Sponsored by Vifor Pharma

Iron deficiency: an important comorbidity - Welcome.

Event : Heart Failure 2018

  • Session : Iron deficiency: an important comorbidity
  • Speaker : P Van Der Meer (Groningen,NL)
  • Sponsored by Vifor Pharma

Panel discussion and close - Hyperkalaemia and iron deficiency: time for a paradigm change.

Event : ESC Congress 2018

  • Session : Co-morbidities in chronic heart failure – time for paradigm shifts in the management of hyperkalaemia and iron deficiency
  • Speaker : J Butler (Atlanta,US), G Filippatos (Athens,GR), S Anker (Berlin,DE), P Van Der Meer (Groningen,NL), I Pina (Detroit,US)
  • Organised by Charité supported with an educational grant from Vifor

Renin-angiotensin-aldosterone system inhibitors therapy benefits and challenges in cardio-renal patients.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : P Van Der Meer (Groningen,NL)
  • Sponsored by Vifor Pharma

Why is iron deficiency recognized as an important comorbidity in heart failure?

Event : Heart Failure 2018

  • Session : Iron deficiency: an important comorbidity
  • Speaker : P Van Der Meer (Groningen,NL)
  • Sponsored by Vifor Pharma

Changing the treatment paradigm of hyperkalaemia management to enable and optimise renin-angiotensin-aldosterone system inhibitor (RAASi) therapy.

Event : ESC Congress 2017

  • Session : Hyperkalaemia and iron deficiency: how too much or too little may affect the heart
  • Speaker : P Van Der Meer (Groningen,NL)
  • Sponsored by Vifor Pharma

Concomitant renal failure: how to adjust treament.

Event : Heart Failure 2017

  • Session : Comorbidities: prequel or sequel to heart failure
  • Speaker : P Van Der Meer (Groningen,NL)

Discharge recommendations.

Event : Heart Failure 2017

  • Session : Emergencies in peripartum cardiomyopathy
  • Speaker : P Van Der Meer (Groningen,NL)

Discussion: iron deficiency in patients with heart failure: implementing the guidelines in your clinical practice.

Event : Heart Failure 2017

  • Session : Iron deficiency in patients with heart failure: implementing the guidelines in your clinical practice
  • Speaker : P Van Der Meer (Groningen,NL), T McDonagh (London,GB), S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma

Managing contemporary heart failure with reduced ejection fraction therapies – Clinical case discussion.

Event : Heart Failure 2017

  • Session : Contemporary management of patients with Heart Failure with reduced Ejection Fraction (HFrEF)
  • Speaker : P Van Der Meer (Groningen,NL)
  • Sponsored by Novartis

Managing potassium to optimize therapy for heart failure.

Event : Heart Failure 2017

  • Session : New opportunities for an old problem: lowering potassium to maximize heart failure therapy
  • Speaker : P Van Der Meer (Groningen,NL)
  • Organised by Lorraine University, supported by an unrestricted educational grant from AstraZeneca

Panel Q&A / Discussion.

Event : Heart Failure 2017

  • Session : New opportunities for an old problem: lowering potassium to maximize heart failure therapy
  • Speaker : F Zannad (Vandoeuvre,FR), J Cleland (Glasgow,GB), P Van Der Meer (Groningen,NL)
  • Organised by Lorraine University, supported by an unrestricted educational grant from AstraZeneca

State of the Art: disease modelling with iPSC.

Event : ESC Congress 2017

  • Session : Cardiac regeneration and disease modelling with induced Pluripotent Stem Cells (iPSC)
  • Speaker : P Van Der Meer (Groningen,NL)

Hyperkalemia: novel treatment strategies to manage potassium levels in heart failure.

Event : Heart Failure 2016

  • Session : Optimizing RAAS inhibition in heart failure: novel treatment considerations for the management of hyperkalemia
  • Speaker : P Van Der Meer (Groningen,NL)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from AstraZeneca

Interactive case discussion: what are the implications of new treatment options in achieving better outcomes in heart failure patients?

Event : Heart Failure 2016

  • Session : Implications of novel treatment strategies for the management of hyperkalemia in heart failure
  • Speaker : F Zannad (Vandoeuvre,FR), P Van Der Meer (Groningen,NL)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from AstraZeneca

Novel treatment strategies to manage potassium levels in heart failure.

Event : Heart Failure 2016

  • Session : Implications of novel treatment strategies for the management of hyperkalemia in heart failure
  • Speaker : P Van Der Meer (Groningen,NL)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from AstraZeneca

Other comorbidities.

Event : Heart Failure 2016

  • Session : The new ESC Guidelines: Focus on co-morbidities
  • Speaker : P Van Der Meer (Groningen,NL)

Cardiovascular toxicity of chemotherapeutic agents.

Event : EHRA 2015

  • Session : Cancer treatment and cardiotoxicity
  • Speaker : P Van Der Meer (Groningen,NL)

Hypertrophic cardiomyopathy.

Event : Heart Failure 2015

  • Session : Cardiomyopathies: what are the mechanisms?
  • Speaker : P Van Der Meer (Groningen,NL)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are